文献速递银屑病与炎症性皮肤病药疹与重症皮肤不良反应

炎症性肠病患者银屑病的管理:美国国家银屑病基金会医学委员会

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
PubMed 文献 · J Am Acad Dermatol · 2018-01-01

该系统综述检索1947年1月1日至2017年2月14日文献,评估银屑病合并炎症性肠病的治疗方案。英夫利西单抗和阿达木单抗对银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病均显示疗效;乌司奴单抗对银屑病、银屑病关节炎和克罗恩病显示疗效; certolizumab对银屑病关节炎和克罗恩病显示疗效;依那西普、司库奇尤单抗、布罗达鲁单抗和依奇珠单抗对银屑病和银屑病关节炎显示疗效但可能加重或诱发炎症性肠病。

要点

  • 英夫利西单抗和阿达木单抗对银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病均显示疗效。
  • 乌司奴单抗对银屑病、银屑病关节炎和克罗恩病显示疗效。
  • 依那西普、司库奇尤单抗、布罗达鲁单抗和依奇珠单抗可能加重或诱发炎症性肠病。

核心结论

  • 英夫利西单抗和阿达木单抗对银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病均显示疗效;其他药物仅对部分而非全部上述适应症显示疗效。

研究设计与样本

  • 系统文献检索1947年1月1日至2017年2月14日关于生物制剂和系统性银屑病药物治疗银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病的临床研究。
  • 共识别2282篇文章,筛选出132篇;优先选择随机对照双盲研究,若无则选择次高等级证据。

主要发现

  • 英夫利西单抗和阿达木单抗在银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病中均显示疗效。
  • 乌司奴单抗在银屑病、银屑病关节炎和克罗恩病中显示疗效。
  • certolizumab在银屑病关节炎和克罗恩病中显示疗效。
  • 依那西普、司库奇尤单抗、布罗达鲁单抗和依奇珠单抗在银屑病和银屑病关节炎中显示疗效,但可能加重或诱发炎症性肠病。
  • 古塞奇尤单抗在银屑病中显示疗效。

关键数值与推荐

  • 英夫利西单抗和阿达木单抗对银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病均显示疗效。
  • 乌司奴单抗对银屑病、银屑病关节炎和克罗恩病显示疗效。
  • certolizumab对银屑病关节炎和克罗恩病显示疗效。
  • 依那西普、司库奇尤单抗、布罗达鲁单抗和依奇珠单抗对银屑病和银屑病关节炎显示疗效但可能加重或诱发炎症性肠病。
  • 古塞奇尤单抗对银屑病显示疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 目前尚无专门针对银屑病合并炎症性肠病治疗的已知临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected. RESULTS: Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis. LIMITATIONS: There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD. CONCLUSIONS: Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018. PMID: 29332708. doi:10.1016/j.jaad.2017.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。